EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Top advances of the year: Uterine cancer

Britt K Erickson, Brian Slomovitz, Matthew Powell, Ramez N Eskander iD

Cancer · 15.07.2024 · 130 (14) · 2409-2412

DOI: 10.1002/cncr.35321 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer, online erschienen am 15.04.2024. Verfasst von Britt K Erickson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics, Gynecology, and Women's Health, University of Minnesota, Minneapolis, Minnesota, USA. Hauptthemen laut MEDLINE: Immunotherapy, Uterine Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometrial cancer continues to be the only gynecologic malignancy with a rising incidence and mortality, with both regional and global implications. Combination carboplatin and paclitaxel has been the recognized chemotherapy backbone for the treatment of advanced‐stage or recurrent disease, with modest clinical outcomes. Over the last year, significant advances were achieved in improving oncologic outcomes by capitalizing on the molecular characterization of this heterogenous disease. These advances include incorporation of immunotherapy, identification of effective hormonal approaches, the evolution of antibody drug conjugates, and utilization of alternate targeted therapies. Plain Language Summary The molecular characterization of endometrial cancer has been critical in informing novel treatment strategies. Over the past year, significant gains have been made via the incorporation of immunotherapy, hormonal combinations as well as antibody drug conjugates.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyUterine NeoplasmsHumansFemaleAntineoplastic Combined Chemotherapy ProtocolsEndometrial NeoplasmsMolecular Targeted TherapyImmunoconjugatesPaclitaxelCarboplatin

Stichwörter der Autor:innen

CKD 4/6HER2TP53TROP2antibody drug conjugateshormonal therapyimmune checkpoint inhibitionimmunotherapy

Substanzen

ImmunoconjugatesPaclitaxelCarboplatin

Autor:innen und Institutionen

  • Department of Obstetrics, Gynecology, and Women's Health, University of Minnesota, Minneapolis, Minnesota, USA.
  • Division of Gynecologic Oncology, Mount Sinai Medical Center, Miami Beach, Florida, USA.
  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Division of Gynecologic Oncology, Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Diego Moores Cancer Center, La Jolla, California, USA.

ORCID-Profile: Ramez N Eskander

Zitieren

APA

Erickson, B. K., Slomovitz, B., Powell, M., & Eskander, R. N. (2024). Top advances of the year: Uterine cancer. Cancer, 130(14), 2409-2412. https://doi.org/10.1002/cncr.35321

Vancouver

Erickson BK, Slomovitz B, Powell M, Eskander RN. Top advances of the year: Uterine cancer. Cancer. 2024;130(14):2409-2412. doi:10.1002/cncr.35321

BibTeX
@article{Erickson2024,
  author = {Erickson, Britt K and Slomovitz, Brian and Powell, Matthew and Eskander, Ramez N},
  title = {Top advances of the year: Uterine cancer},
  journal = {Cancer},
  year = {2024},
  volume = {130},
  number = {14},
  pages = {2409--2412},
  doi = {10.1002/cncr.35321}
}
Kostenlos starten →